Masimo, a pioneer in the field of medical monitoring technology, is marking its 33rd anniversary with the exciting limited market launch of the W1™ health watch. This cutting-edge wrist-worn device is designed for consumers, providing continuous and precise health measurements that leverage Masimo’s extensive experience in hospital pulse oximetry. The W1 tracks a variety of health metrics, including oxygen saturation, pulse rate, and respiration rate, while also offering features such as step counting and fall detection.
Since its inception in 1989, Masimo has transformed the landscape of pulse oximetry with its innovative Measure-through Motion and Low Perfusion™ SET® technology. This advanced method has consistently demonstrated superior performance compared to traditional pulse oximetry techniques in numerous studies. Its impact is particularly notable in critical congenital heart disease screening for newborns and in minimizing complications across various medical environments. The W1 health watch represents the latest advancement in this technology, tailored for everyday consumer use.
As part of the limited market release, Masimo is inviting early adopters to experience the W1, with up to 10,000 units available at a special discounted price. Participants will have the opportunity to provide valuable feedback, which will be instrumental in refining the product. The W1 seamlessly connects to the Masimo Personal Health app via secure Bluetooth®, offering users continuous health data and insights that are essential for effective personal health management.
Tommy Haas, a former professional tennis player, has lauded the W1 for its ease of use in tracking vital signs, emphasizing its potential to improve athletic performance and recovery. Additionally, the W1 is set to support telehealth applications outside the U.S., facilitating remote patient monitoring for individuals managing chronic health conditions.
Dr. Abeer Bakhsh from the Prince Sultan Cardiac Center in Saudi Arabia has highlighted the W1’s comfort and reliability in monitoring patients with heart failure remotely. The device is designed to integrate with Masimo’s SafetyNet® platform, ensuring smooth data transmission and enhancing overall patient safety.
Joe Kiani, the Founder and CEO of Masimo, expressed his enthusiasm about making hospital-grade monitoring technology available to consumers. The W1 builds on Masimo’s legacy of innovation, which spans from SET® pulse oximetry to sophisticated hospital monitors and remote monitoring solutions, now accessible to a wider audience.
Although the Masimo W1 has not yet received FDA clearance, its launch signifies a major advancement in the effort to provide advanced health monitoring solutions to consumers globally.